Frank Witney Joins RareCyte Board of Directors
Recognized life science and diagnostics industry leader strengthens RareCyte leadership
Seattle, WA USA, August 18, 2016 – RareCyte, Inc., a provider of globally deployable next-generation automated tools for characterizing and isolating rare cells from liquid biopsies and tissue samples announces that Frank Witney has joined its board of directors.
“We are delighted to welcome Frank to RareCyte’s Board. Frank brings significant market knowledge and business leadership across the diagnostics and the life sciences industries,” said Ron Seubert, Chairman and CEO, RareCyte. “As we continue to grow and provide complete solutions for rare cell analysis, Frank’s commercial expertise as well as his understanding of the scientific needs of our customers will be invaluable.”
Most recently, Dr. Witney served as President and CEO of Affymetrix, Inc., a leader in genomic and cellular analysis (now part of Thermo Fisher Scientific). Previously, Dr. Witney was President and CEO of Dionex Corp., a market leading ion and high performance liquid chromatography company. Prior to that, Dr. Witney first joined Affymetrix when it acquired Panomics Inc., which he led as President and CEO. Dr. Witney also served as President of PerkinElmer's Drug Discovery Tools division following the acquisition of Packard BioScience in 2001, where he served as President and COO. Dr. Witney also held several leadership positions at Bio-Rad Laboratories.
Dr. Witney was a post-doctoral fellow at the National Institutes of Health and earned his Ph.D. in molecular and cell biology from Indiana University and bachelor’s degree in microbiology from the University of Illinois. He holds Board positions for PerkinElmer, Inc., Cerus Corporation, Exagen Diagnostics and is currently Chairman for Gyros Protein Technologies AB.
“I am extremely impressed with the technical advancements and commercial progress RareCyte has made,” stated Dr. Witney. “Numerous high-profile customers in biopharmaceutical and clinical research organizations have invested in the RareCyte platform and are realizing the value it brings. I am pleased to contribute to the company’s rapid growth and bright future.”
RareCyte’s rare cell liquid and tissue biopsy platform includes the AccuCyte® blood separation system, the CyteFinder® high resolution microscopic scanning instrument and the CytePicker® cell capture device. The integrated system enables the imaging, analysis and retrieval for downstream characterization of rare single cells. Current applications include circulating tumor cell (CTC) analysis, detection of rare immune cell sup-populations, fetal cell testing and identification of infectious pathogens.
“Frank has an extraordinary track record in building life science companies. His insights in developing new applications for innovative technologies will be instrumental to RareCyte as it expands its commercial efforts. We are thrilled Frank will be joining the RareCyte Board,” said Robert Shepler, a RareCyte Board member and managing director of Telegraph Hill Partners.
About RareCyte, Inc.
RareCyte is a life science company that offers high-performance easy to use, next-generation tools for the analysis and capture of rare, individual cells from liquid biopsies and tissue samples. RareCyte’s systems are used by academic institutions and commercial organizations for a range of applications in oncology, prenatal testing and infectious disease. For more information about RareCyte, visit www.rarecyte.com.
RareCyte will be exhibiting at the following upcoming scientific conferences:
SABCS San Antonio Breast Cancer Symposium
December 6-10, 2016
AACR Annual Meeting 2017 - American Association for Cancer Research
April 1-5, 2017
2017 ASCO Annual Meeting - American Society of Clinical Oncology
June 2-6, 2017
Presentations will highlight cancer applications of single-cell genomics, multi-parameter phenotyping and PDX models.
Seattle, WA USA, April 11, 2016 - At the upcoming annual meeting of the American Association for Cancer Research (New Orleans, April 16-20, 2016) RareCyte, Inc., its collaborators and customers will be presenting results from five collaborative oncology research projects.
The presentations will report novel applications of the company’s AccuCyte® - CyteFinder® - CytePicker® platform to identify, visually characterize, pick individual circulating tumor cells (CTCs) and perform single-cell molecular analysis. In aggregate, the results from the collaborations will demonstrate the technology’s exceptional scientific value to current clinical research and and future translational medicine applications.
Presentations at the AACR meeting will include:
Evolving genomic profiles of individual CTCs during the course of treatment of a triple-negative breast cancer patient in the ITOMIC clinical trial. Analysis of mutations discovered in CTCs and circulating tumor DNA will be reported, providing valuable insight into cancer heterogeneity. (Presentation 498)
Studies of breast cancer patient-derived xenograft (PDX) models. The investigation of CTCs and CTC clusters in detecting tumor-specific mutations will be described, along with preliminary results in understanding their predictive value for examining treatment response and long-term outcomes. (Presentation 3969)
A study of methods for whole genome amplification (WGA) as applied to a single CTC and small pools of CTCs. The findings show significance for the rapidly developing use of single-cell molecular information in selecting cancer therapeutics and monitoring cancer evolution. (Presentation 3615)
A prostate CTC study extending slide-based investigation to immunohistochemical analysis, 6-channel fluorescence phenotyping and molecular analysis of individual CTCs for identification of lineage-specific biomarkers and drug targets or resistance markers. (Presentation 4959)
A study demonstrating the utility of small blood volumes for CTC analysis. Data will show PDX lines used to validate small volume mouse blood samples for single CTC analysis using the RareCyte platform. (Presentation 646)
“We are delighted to see the presentation of results from these five studies,” said Michael A. Nemzek, President of RareCyte. “They are representative of our many ongoing collaborations. Studies like these suggest a time soon when the benefits of single CTC analysis in liquid biopsies will become widely applicable for the assessment and treatment of cancer.” Non-invasive liquid biopsies are widely thought to be a future standard allowing frequent assessment of tumor progression and any adjustment of treatment. Directly examining individual cancer cells within the blood with RareCyte technology enables the next generation of liquid tissue biopsies.
RareCyte’s flagship platform, comprised of AccuCyte®, CyteFinder® and CytePicker® technologies, was commercialized in 2015. The company has established sales in the Americas, Europe and Asia and currently counts a large and growing list of customers and collaborators worldwide. RareCyte products will be on exhibit at AACR at booth 1759.
About RareCyte, Inc.
RareCyte is a life science company providing an easy-to-use, next-generation liquid biopsy platform for precise analysis and retrieval of rare, individual cells from blood samples. Its automated platform is used at leading academic institutions and commercial organizations in several countries performing a range of applications in oncology, prenatal testing and infectious disease. For more information about RareCyte, visit www.rarecyte.com.
RareCyte Announces CRADA with NCI in Immunology/Oncology
Seattle, WA USA, March 14, 2016 – RareCyte, Inc., a provider of globally deployable next-generation liquid biopsy tools for characterizing and isolating rare cells in blood, announces the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under the terms of the CRADA, RareCyte and the NCI will collaborate over a 3- year period to investigate the use of RareCyte’s technology to identify, characterize, capture and analyze rare immune cell populations as well as individual circulating tumor cells (CTCs) derived from preclinical and clinical studies conducted by the NCI.
The specific goals of the CRADA include the detection, characterization, single cell retrieval, and analysis of rare circulating immune cells, such as natural killer T (NKT) cells and antigen-specific conventional T cells, and CTCs derived from preclinical and clinical studies conducted by the NCI and the development of assays showing response to immunotherapy and the extent of cancer progression.
The study will be led by NCI principal investigator, Jay A. Berzofsky MD, PhD, chief of the Vaccine Branch of the NCI. He and Masaki Terabe, PhD, deputy section chief and head of the Cancer Immunology Unit, have deep expertise in T cell immunology and tumor immunology and translation of basic immunological research to strategies to develop vaccines. Joining them will be Lauren V. Wood MD, clinical director of the NCI Vaccine Branch, who has done extensive clinical research in cancer and HIV infection and clinical translation of therapeutic vaccine platforms into first-in-human trials. The group will also collaborate with Jane Trepel who heads the Preclinical Development Core within the NCI Developmental Therapeutics Branch, which focuses on drug development and currently participates in more than 50 clinical trials.
“With advances in cancer immunotherapy, a significant challenge remains in identifying immunologic responses that correlate with beneficial clinical outcomes,” stated Eric Kaldjian, MD, chief medical officer of RareCyte and CRADA collaborator principal investigator. “The ability to characterize the immune response is an important aspect of personalized approaches for patients undergoing cancer immunotherapy. We believe that RareCyte’s technology makes this possible.”
RareCyte’s integrated rare cell separation, identification and retrieval platform starts with the AccuCyte® blood separation system for comprehensive collection and transfer to slide of the nucleated cell fraction of a blood draw containing leukocytes and CTCs. Slides are then stained in the same manner as tissue sections or cytology preparations followed by high resolution microscopic scanning with the CyteFinder® instrument. Using up to 6-channel immunofluorescence staining and detection, rare immune cell subsets may be identified by the RareCyte platform. The method has a high recovery rate (>90%) and can detect a single cancer cell in a tube of blood containing 40-50 million leukocytes. Ultimately, individual cells can be captured for genomic analysis using the CytePicker® retrieval device incorporated in the CyteFinder instrument.
About RareCyte, Inc.
RareCyte is a life science company providing an easy-to-use, next-generation liquid biopsy platform for precise analysis and retrieval of rare, individual cells in blood. We have a long pedigree in developing advanced precision life science systems used in thousands of labs worldwide. Our customers do leading edge work at prominent academic institutions and commercial organizations in several countries performing a range of applications in oncology, prenatal testing and infectious disease.